In this study, starting from 4-amino-5-(4-chlorobenzyl)-2,4-dihydro-3H-1,2, 4-triazole-3-one (1), the 4-Amino-5-(4-chlorobenzyl)-2-undecyl-2,4-dihydro-3H-1,2,4-triazol-3-one (2) was first synthesized and this compound was converted to Schiff base derivatives (3a-e). In the second step of the study, the 2-[3-(4-chlorobenzyl)-5-oxo-1-undecyl-1,5-dihydro-4H-1,2,4-triazole-4-yl]acetohydrazide (6), which was used as a key product in the synthesis of many heterocyclic compounds was synthesized in four steps, and then this compound was converted into methylidene acetohydrazide (7a-e), thiosemicarbazide (8a-e), and 1,2,4-triazole-5-thione (9a-e) derivatives. Also, in the last part of the study, 1,2,4-triazole-5-thione derivatives were changed into Mannich bases (10a-b) bearing a 4-phenylpiperazine ring. These new compounds were tested with regard to pancreatic lipase (PL) inhibition activity, and compound 3b, 3d, 7d, 8d, and 9d showed a considerable anti-lipase activity at various concentrations. The activity of compounds 7b (IC 50 = 1.45 ± 0.12 μM) was the highest in terms of IC 50 , comparable to that of orlistat, a well-known PL inhibitor used as an antiobesity drug.
